

SUGGESTED READINGS

Therapeutic HIV Vaccines and Broadly Neutralizing Antibodies

Magdalena E. Sobieszczyk, MD, MPH

Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. *N Engl J Med*. 2016;375(21):2037-2050.

Cohen YZ, Caskey M. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. *Curr Opin HIV AIDS*. 2018;13(4):366-373.

Gama L, Koup RA. New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. *Annu Rev Med*. 2018;69:409-419.

Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. *J Int AIDS Soc*. 2015;18:20497.

Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature*. 2018;561(7724):479-484.

Scheid JF, Horwitz JA, Bar-On Y, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. *Nature*. 2016;535(7613):556-560.

Seddiki N, Levy Y. Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies. *Curr Opin HIV AIDS*. 2018;13(2):119-127.

Sneller MC, Justement JS, Gittens KR, et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. *Sci Transl Med*. 2017;9(419)

Interactive PrEP Case-Based Panel Discussion

Roy M. Gulick, MD

Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. *Lancet HIV*. 2018;5(11):e629-e637.

Gunthard HF, Calvez V, Paredes R, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society–USA panel. *Clin Infect Dis*. 2018;67:1-11.

McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2016;387(10013):53-60.

Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. *N Engl J Med*. 2015;373(23):2237-2246.

Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. *J Virus Erad.* 2018;4(4):215-224.

Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA panel. *JAMA.* 2018;320(4):379-396.

US Public Health Service. Pre-exposure prophylaxis for the prevention of HIV infection in the United States - 2017. A Clinical practice guideline. <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>. Accessed on March 14, 2019.

Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. *Clin Infect Dis.* 2015;61(10):1601-1603.

ART in Women and Pregnancy: InSTIs, Comorbid Conditions, and Other Current Issues *Sharon A. Nachman, MD*

World Health Organization HIV/AIDS Programme, Centers for Disease and Control and Prevention (CDC), and The Global Fund. HIV drug resistance report 2017. <https://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831-eng.pdf?sequence=1>. Accessed on March 14, 2019.

Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. *Lancet Glob Health.* 2018;6(7):e804-e810.

US Department of Health and Human Services and AIDS Info. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0>. Accessed on March 14, 2019.

Fowler MG, Qin M, Fiscus SA, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. *N Engl J Med.* 2016;375(18):1726-1737.

Imbard A, Benoist JF, Blom HJ. Neural tube defects, folic acid and methylation. *Int J Environ Res Public Health.* 2013;10(9):4352-4389.

Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. *N Engl J Med.* 2018;379(10):979-981.

The antiretroviral pregnancy registry. <http://www.apregistry.com/>. Accessed on March 14, 2019.

Management of Comorbidities in Older Adults with HIV Infection *Kristine M. Erlandson, MD, MS*

Boyd CM, et al. Framework for decision-making for older adults with multiple chronic conditions. *J Am Geriatr Society.* 2019;

Montoya JL, Jankowski CM, O'Brien KK, et al. Evidence-informed practical recommendations for increasing physical activity among persons living with HIV. *AIDS*. 2019;

Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? *J Gerontol A Biol Sci Med Sci*. 2014;69(7):833-842.

Tinetti M, Huang A, Molnar F. The Geriatrics 5M's: A New Way of Communicating What We Do. *J Am Geriatr Soc*. 2017;65(9):2115.

Websites

www.HIV-Age.org

www.Eprognosis.com

Deprescribing.org

www.hiv.gov/hiv-basics/living-well-with-hiv/

www.poz.com/basics/hiv-basics/hiv-aging

<https://www.nia.nih.gov/news/aging-hiv-responding-emerging-challenge>